Sun Pharma Q2 Sales Rise 11.8% To Rs 161 Billion, Adjusted Profit At Rs 31.62 Billion

What happened

Sun Pharmaceutical Industries reported second-quarter FY27 sales of Rs 161 billion, up 11.8% year on year, and adjusted net profit of Rs 31.62 billion. The company also reported India formulation sales of Rs 55.52 billion and EBITDA of Rs 47.44 billion.

Confirmed

Global impact / market context

India’s strong sales and its substantial contribution to quarterly revenue point to this business as a driver of growth. If the trend continues, it could support company-wide sales; however, EBITDA, a measure of operating earnings, grew more slowly than sales, suggesting costs may be absorbing some growth.

Analyst inference

The reported quarter combines growth in India, emerging markets and the rest of the world, though the supplied figures give detail mainly for India. Adjusted net profit excludes certain items; reported net profit was Rs 19.89 billion, showing the distinction matters when comparing earnings.

Analyst inference

What to watch

1. Look for further updates on India formulation sales and whether growth there continues to support Sun Pharma’s overall revenue in subsequent quarters. Analyst inference
2. Compare future sales growth with EBITDA growth and the reported margin, which means the portion of sales left after operating costs, to gauge profit conversion. Analyst inference
3. Watch whether research and development spending changes in future quarters, as this investment can affect costs now and potentially support new medicines and future sales. Analyst inference

Evidence

• Original source link unavailable